(Reuters) - Medical device maker Medtronic Inc (MDT.N) said U.S. regulators approved its new catheter system for treating a common heart rhythm disorder known as paroxysmal atrial fibrillation. MDT is leading the way today in the health sector, with BSX and STJ as tag alongs, it is nothing that BSX has done to improve the company or health care
You are right about the STJ news, they had to withdraw product from the market, giving BSX an automatic market share gain. We will start seeing STJ and MDT withdrawing even more products from the market, because the FDA is on their backs and those companies don't have the talent or resources to design and develop world-class products like BSX.
jbl111 that $2 price gain you referred to since Sept 1 would represent an annualized return of over 100%, I don't know what planet you live on but be it a $1,000 investment or 1 Million that is a significant return. Even for 4 months a $350 return is not chump change on a $1,000 invest, if you think otherwise for a reality check go stick your money in the bank for 4 months and see what you get back.
Well, the Medtronic news is helpful but how does today's news expain where BSX has gone from 9/1 to now vs. MDT or the SPY? As a newsletter writer I follow observed, just like men marry women thinking they'll never change, women marry men believing they can be changed. Men are growth investors, women are value investors. I think I'll go shopping for some shows--with my profits from BSX!